ReachMD Be part of the knowledge.™

Pathology and Laboratory Medicine

53

LikeLikedUnlike

Episodes 1-15 of 37

Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
CME/CE Broadcast Replay
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
- John H. Stone, MD, MPH
  Peer
- Emanuel Della Torre, MD, PhD
  Peer
- Yoh Zen, MD, PhD, FRCPath
  Peer
1.00 credits
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
- Emma Culver, BSc, MD, PhD, FRCP
  Peer
- Louisa Catherine Firmin, MBChB, MRCS, FRCR
  Peer
0.25 credits
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
- Yasmin Genevieve Hernandez-Barco, MD
  Peer
- Avinash Kambadakone-Ramesh, MD, DNB, FRCR
  Peer
0.25 credits
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
CME/CE
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
- John H. Stone, MD, MPH
  Peer
- Bart K. Chwalisz, MD
  Peer
- Marcela Marsiglia, MD, PhD
  Peer
0.50 credits
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
CME/CE
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
- Giacomo Quattrocchio, MD
  Peer
- Lynn D. Cornell, MD
  Peer
0.50 credits
Consensus Recommendations for Use of p16/Ki-67 Dual Staining Cytology in the Management of Individuals Testing Positive for HPV
CME/CE
Consensus Recommendations for Use of p16/Ki-67 Dual Staining Cytology in the Management of Individuals Testing Positive for HPV
- Warner K. Huh, MD
  Peer
- Kimberly Levinson, MD, MPH
  Peer
0.25 credits
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
- Benjamin Levy, MD
  Peer
- Alexander Spira, MD, PhD, FACP
  Peer
0.25 credits
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
- Jyoti Patel, MD
  Peer
- Pasi Antero Jänne, MD, PhD
  Peer
0.50 credits
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
- Helena Yu, MD
  Peer
0.25 credits
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
MinuteCE®
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
- Charu Aggarwal, MD, MPH
  Peer
1.00 program credits
MinuteCE®
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
- Charu Aggarwal, MD, MPH
  Peer
- Alexander Drilon, MD
  Peer
1.00 credits 9 episodes
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
MinuteCE®
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
- Charu Aggarwal, MD, MPH
  Peer
- Alexander Drilon, MD
  Peer
1.00 program credits
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
MinuteCE®
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
- Charu Aggarwal, MD, MPH
  Peer
1.00 program credits
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
MinuteCE®
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
- Charu Aggarwal, MD, MPH
  Peer
- Alexander Drilon, MD
  Peer
1.00 program credits
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
MinuteCE®
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
- Charu Aggarwal, MD, MPH
  Peer
- Alexander Drilon, MD
  Peer
1.00 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended